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ABSTRACT: Stimulated Raman scattering (SRS) microscopy represents a powerful method for imaging label-free drug
distribution with high resolution. SRS was applied to image label-free ponatinib with high sensitivity and specificity in live
human chronic myeloid leukemia (CML) cell lines. This was achieved at biologically relevant, nanomolar concentrations,
allowing determination of ponatinib uptake and sequestration into lysosomes during the development of acquired drug
resistance and an improved understanding of target engagement.
■ INTRODUCTION
Despite the identification of an unprecedented number of
potential new drug targets over the past two decades, and an
accompanying intense investment in the generation of NCEs
with improved potency and selectivity, currently only 1 in 10
clinical candidates progresses to regulatory approval.1 This
major loss in investment by drug developers can be analyzed
from the viewpoint of the physicochemical properties of drug
candidates,2 but these studies do not provide clear indicators
for how to reduce attrition rates.3 Some of the highest pipeline
attrition rates are seen in the development of chemo-
therapeutics.4 As a plethora of new, targeted chemotherapeu-
tics enter the clinic and, with the development of resistance to
these agents, alternative approaches are urgently required to
optimize their development and use. A shift toward
determining critical information through the use of relevant
cell-based assays at an earlier stage in the pipeline5 could result
in a much cheaper and more effective development process.6
Stimulated Raman scattering (SRS) microscopy generates
image contrast using the Raman active vibrational frequency of
a given chemical bond, providing information on the
biochemical composition of tissues and allowing label-free
visualization for a number of biomedical applications including
drug interactions.7,8 SRS is distinguished by a number of key
features:
(1) Fast acquisition speeds (orders of magnitude faster than
those achieved with spontaneous Raman), good photo-
stability, and a lack of phototoxicity, which together
allow real-time imaging.
(2) A linear relationship between signal intensity and
chemical concentration, which enables quantitative
imaging.
(3) Multiple acquisition wavelengths, which allows drug
distribution within cells to be mapped onto subcellular
features providing intracellular registration.
(4) Multimodal imaging (SRS and fluorescence), which
allows image overlay with cell- or tissue-specific
markers.9,10
Combined, these characteristics ensure that SRS imaging
provides a unique platform to understand drug distribution
within individual cells, thus distinguishing it from other
technologies, such as whole-body autoradiography and liquid
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chromatography−mass spectrometry (LC-MS), that are
typically used to monitor drug distribution.11,12
Raman imaging was initially developed as a label-free
technique for visualization of biomolecules including lipids
and proteins, and more recently the development of alkynes
(CC) as nonlinear vibrational tags for imaging small
biomolecules using SRS microscopy has extended the
applicability of this approach.13,14 Alkynes are both chemically
and Raman spectroscopically biorthogonal as they do not react
with endogenous biomolecules and do not exist inside cells.
The CC stretching motion can hence be detected in the
Raman “cellular-silent” region (1800−2800 cm−1). This also
presents an optimal region for drug imaging, as there is
minimal contribution from endogenous cellular biomolecules,
thus improving detection sensitivity.8,15 In this study, we utilize
the advantages of an alkyne-based imaging approach to assess
label-free drug uptake and distribution in cellular models of
resistance using ponatinib (1),16 a tyrosine kinase inhibitor
with regulatory approval for the treatment of chronic myeloid
leukemia.
■ RESULTS AND DISCUSSION
Ponatinib (1) has an inherent alkyne moiety in its structure
providing the potential for imaging its cellular localization in
the Raman “cellular-silent” region (Figure 1a,b), without the
addition of bulky tags such as fluorophores, which can
negatively impact on the biological activity of drugs. In SRS,
two synchronized lasers, the pump and the Stokes beam are
used to excite a specific molecular vibration (Figure 1c). To
visualize a chemical bond of interest, the frequency difference
between the pump beam and the Stokes beam is tuned to
match the chosen vibration (ωυ), allowing stimulated Raman
scattering to take place in addition to the inherently weak
spontaneous Raman scattering.
Predicting the Intensity and Frequency of Raman
Signals by DFT. Density functional theory (DFT) calcu-
lations have previously been used to predict theoretical Raman
intensities (IRam),
8,15 while experimentally observed Raman
intensities have been compared with the intensity of the alkyne
resonance in the nucleoside analogue ethynyl deoxyuridine
(EdU) to give relative intensity to EdU (RIE) values.17 We
have combined these two approaches to give a series of
calculated RIE values (cRIE) to facilitate comparison of the
predicted intensity values for signals in the “cellular-silent”
region. DFT calculations have also, very recently been used to
predict the changes in Raman vibrational frequencies that
result from primary drug metabolism.18 Thus, we have used a
series of DFT calculations to establish whether the acquisition
of SRS images at a single vibrational frequency for the alkyne
(Figure 1b, CC, 2221 cm−1) would provide an accurate
assessment of the ponatinib concentration within a cell
(Supporting Information (SI), Table S1).
The piperidine unit in ponatinib means that it is susceptible
to lysosomal trapping through protonation.19,20 However, in
our DFT calculations, both the parent drug and its protonated
counterpart were predicted to have very similar frequencies for
the alkyne resonance, with a slight decrease in cRIE value upon
protonation (SI, Table S1). Hence, it was determined that SRS
imaging at a single wavenumber would allow assessment of
ponatinib concentrations across the whole cell environment,
independent of subcellular variations in pH. Previous studies
have identified the primary metabolites of ponatinib as its N-
oxide and N-desmethyl analogues, together with dihydroxy-
lated forms.21−23 As the chemical perturbations in these two
major metabolites is distal to the alkyne vibrational motif, a
large change in IRam is not expected. This conclusion was
confirmed by DFT calculations (SI, Table S1), which show
similar cRIE values to the parent drug, with only minimal shifts
in the predicted Raman frequencies for the alkyne absorption.
The formation of these metabolites has been shown to be
catalyzed predominantly by the P450 enzyme CYP3A4.23,24
Western blot analysis confirmed expression of CYP3A4 protein
in both KCL22 and KCL22Pon‑Res cells (Figure 2a). However,
we identified ponatinib as the predominant peak by LC-MS
analysis with only trace amounts of the N-desmethyl and
Figure 1. (a) Chemical structure of ponatinib; (b) Raman spectrum
of solid ponatinib. The following peak has been annotated: 2221 cm−1
(CC, ponatinib). Raman spectra were acquired at λex = 532 nm for
10 s using a 50× objective. (c) Energy level diagram showing the
working principle of SRS microscopy.
Figure 2. (a) Expression of CYP3A4 in lysates from KCL22 and
KCL22Pon‑Res cells. β-actin was used as a loading control. (b)
Ponatinib and ponatinib metabolites identified by LC-MS. Cells were
treated with ponatinib for 1 h prior to analysis. Mean values from five
biological repeats expressed relative to ponatinib.
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dihydroxylated metabolites present in the CML cells (Figure
2b).
Thus, given the relatively low concentrations of these
metabolites in the CML cell lines, and the minimal shifts in
their predicted Raman frequencies, their presence is not
expected to affect SRS imaging of the intracellular distribution
of ponatinib. This conclusion is in sharp contrast to recent
imaging studies conducted on neratinib using Raman
microscopy, where metabolism directly affects the Raman
active motif in the drug and significant vibrational shifts are
observed.18
Applications of SRS Imaging of Intracellular Drug
Concentrations. With the validity of imaging the alkyne in
ponatinib by Raman to assess its intracellular distribution
established, we conducted a series of experiments to
demonstrate the utility of this approach experimentally. CML
results from expression of the constitutively active tyrosine
kinase BCR-ABL and treatment with TKIs, such as ponatinib,
which target BCR-ABL, have been successful in providing
improved life expectancy, although resistance prevents long-
term durable responses in many patients.25 There is currently
no information on the subcellular distribution and uptake of
Figure 3. (a−c) Imaging ponatinib uptake in KCL22Pon‑Res cells. KCL22Pon‑Res cells were treated with DMSO (0.0003%, v/v) or ponatinib (500
nM) for 1, 6, 24, or 48 h (left to right). SRS images acquired at (a) 2940 cm−1 (CH3, proteins); (b) 2221 cm
−1 (CC, ponatinib); (c) 2257 cm−1
(off-resonance). Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power p300, gain 2 with false colors applied to different
detection wavenumbers. Scale bars: 10 μm. (d) Mean ponatinib intensity per cell quantified from 2221 cm−1 in n = 30 cells, three biological
repeats. The Mann−Whitney test was used to compare ponatinib Raman intensity values against the DMSO control.
Figure 4. Multimodal imaging and quantitative assessment of ponatinib uptake in KCL22 and KCL22Pon‑Res cell lines. KCL22 cells were treated
with (a) DMSO (0.0003%, v/v) or (b) ponatinib (5 μM, 1 h). KCL22 Pon‑Res cells were treated with (c) ponatinib (5 μM ponatinib, 1 h). SRS
images acquired at (from left to right) 2940 cm−1 (CH3, proteins), 2221 cm
−1 (CC, ponatinib), 2257 cm−1 (off-resonance), TPF image acquired
at 861 nm (Lysotracker Green), overlay of ponatinib and TPF. (d) Mean ponatinib Raman intensity. (e) Maximum ponatinib Raman intensity
inside the vesicles of each individual cell quantified for KCL22 and KCL22Pon‑Res cells that were treated with 5 μM ponatinib for 1 h, n = 30 cells,
three biological repeats. (f) Mean ponatinib Raman intensity quantified outside of the vesicles of individual cells, n = 10, three biological repeats.
Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time, laser power p200 gain 1 with false colors applied to different detection wavenumbers.
Scale bars: 10 μm. The Mann−Whitney test was used to compare ponatinib Raman intensity values, ***p < 0.0001.
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TKIs in the context of drug resistance, and here we
demonstrate the utility of SRS for label-free live cell imaging
of ponatinib in a model of ponatinib resistance.
1. Direct Imaging of Ponatinib at Biologically Relevant
Doses. In a recent study, spontaneous Raman imaging of the
intense fingerprint peak for the TKI neratinib (1386 cm−1)
allowed visualization of the drug following incubation at
nanomolar concentrations; however, this process requires
extended acquisition times (>30 min) using fixed cells.18 In
contrast, SRS microscopy enables up to video-rate imaging
speed, allowing live cell imaging. Hyperspectral SRS imaging,
which enables drug signals in the fingerprint region to be
extracted from the cellular signals, can also been used to follow
drug uptake into cells, although as yet this requires incubation
with micromolar concentrations of analyte and successful
imaging is dependent on 1000-fold enrichment of drugs into
lysosomes.9 The detection sensitivity is the major limitation of
intracellular imaging using SRS, with the micromolar
concentrations required to detect the molecule of interest
often not being physiologically relevant.9,10,13,14,26 To
determine whether we could use SRS to visualize ponatinib
at biologically active concentrations, we chose a concentration
of ponatinib (500 nM), which is close to the GI50 for human
KCL22Pon‑Res CML cells (SI, Table S2). The KCL22Pon‑Res cells
are a ponatinib-resistant cell line that was generated to
understand the drivers of resistance to ponatinib, as resistance
to ponatinib is a recognized clinical problem.27
Cells were treated with ponatinib (500 nM) for up to 48 h
prior to live cell imaging using a custom built SRS
microscope,28 where optimal setup resulted in acquisition
speeds of around 45 s per image. Images were acquired by
tuning the frequency difference between the pump and Stokes
lasers to be resonant with ponatinib (CC, 2221 cm−1, SI,
Figure S1) or intracellular proteins (CH3, 2940 cm
−1) to
provide cellular registration (Figure 3a,b). SRS images can
contain background signals from competing pump−probe
processes such as cross-phase modulation, transient absorp-
tion, and photothermal effects.29 When the signal-to-noise (S/
N) ratio of the SRS image of the drug is low, these background
artifacts can be subtracted to remove the unwanted processes
from the image. This can be achieved by changing the pump
wavelength by a few nanometers, which allows off-resonance
images to be acquired (at a difference of 10−30 cm−1 from the
on-resonance image). This difference image can be used to
distinguish true SRS signals from these artifacts (Figure 3c).30
When imaging with drug concentrations over 5 μM, the SRS
S/N is sufficiently high that subtraction is not necessary to
visualize ponatinib within the cell (see Figure 4a−c).
We analyzed the ponatinib Raman signal intensity (CC,
2221 cm−1) per cell in a population (n = 30) at each time point
and compared it to the values of DMSO treated control cells.
At each time point, there was a significant increase in Raman
signal compared to the control cells, indicating intracellular
accumulation of ponatinib (Figure 3d). Ponatinib puncta
formed in the cells from 6 h onward, with the largest number
of puncta in cells at 24 and 48 h (Figure 3d). This
demonstrates that SRS can be used to image live cells treated
with biologically relevant doses without the need for any
additional labeling or fixation. Many TKIs, including ponatinib
(Figure 1b), have strong Raman bands in the cellular
fingerprint region, and if one of these bands is sufficiently
strong, it can also be used for visualization, as has been
demonstrated for neratinib using spontaneous Raman.18
2. Determination of the Intracellular Localization of
Ponatinib. As ponatinib was concentrated in puncta in the
cytoplasm of the cells, it was important to consider which
cellular organelles these were, as the known target of ponatinib
is the cytoplasmic tyrosine kinase BCR-ABL. Knowing that
ponatinib is a weakly basic drug with a pKa value greater than
eight (pKa1 = 11.4, pKa2 = 8.0)
31 and hence is likely to be
protonated in acidic environments, we predicted that it would
accumulate in lysosomes or related acidic organelles in the cell.
A multimodal imaging approach was used to explore this. Cells
were simultaneously incubated with ponatinib (5 μM, 1 h) or
DMSO (vehicle control, 1 h) and Lysotracker Green (50 nM,
1 h), a cell-permeable fluorescent dye that stains acidic
organelles in live cells (Figure 4). Cells treated with DMSO
and stained with Lysotracker Green (Figure 4a) showed no
SRS signal at 2221 cm−1 (CC, ponatinib on-resonance),
indicating that the presence of the fluorophore does not give a
background SRS signal. In cells treated with ponatinib (Figure
4b,c), we could see colocalization between the SRS signal at
2221 cm−1 and the two-photon fluorescence (TPF) signal
shown in the merged images, with evidence of lower levels of
ponatinib in the cytoplasm, which did not colocalize with the
TPF signal. This demonstrates that the majority of ponatinib is
trapped within acidic organelles, most likely lysosomes, upon
protonation.
There is evidence that lysosomal trapping plays a role in
resistance to TKIs by sequestering them away from their
intracellular targets and thereby reducing target engagement.32
Using the TPF signal as a map, the ponatinib Raman intensity
was quantified in individual cells which showed an increased
ponatinib Raman signal in the resistant KCL22Pon‑Res cells
compared to parental KCL22 cells (Figure 4d,e). The mean
intensity of ponatinib was increased 1.9-fold in the
KCL22Pon‑Res cells compared to parental KCL22 cells (Figure
4d), and the maximum ponatinib signal had increased 2.5-fold
(Figure 4e). There was also a significant increase in the
ponatinib signal within the cytoplasm of the resistant cells
(Figure 4f).
To determine whether differences in lysosomal pH in the
cell lines could be contributing to the increased accumulation
of ponatinib in the KCL22Pon‑Res cells we used Lysosensor
Green, a dye whose fluorescence increases in acidic environ-
ments. There was no significant difference in Lysosensor Green
signal between the KCL22 and KCL22Pon‑Res cells (SI, Figure
S2a,b). However, we did see an increase in expression of the
lysosomal marker LAMP1 in the KCL22Pon‑Res cells (SI, Figure
S2c,d), indicative of increased lysosome number or lysosome
size. To establish whether lysosome biogenesis was differ-
entially regulated in the resistant cells at a transcriptional level,
we looked at nuclear transcription factor EB (TFEB), which is
a master regulator of lysosome biogenesis.33 There was a
significant increase in nuclear TFEB in the KCL22Pon‑Res cells
(SI, Figure S2e,f), indicative of increased lysosome biogenesis
in the resistant cells. This may reflect adaptation of the
resistant cells to allow them to respond to lysosomal stress.
3. Using SRS Imaging to Enhance Target Engagement
Studies. To investigate the importance of lysosomal trapping
on ponatinib−target engagement, we used chloroquine (CQ),
which is a nonspecific autophagy inhibitor that acts as a
lysosomotropic agent, increasing lysosomal pH and ultimately
preventing fusion of autophagosomes and lysosomes. It was
hypothesized that chloroquine treatment could be used to
prevent the increased lysosomal uptake of ponatinib. Pretreat-
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ment of KCL22 and KCL22Pon‑Res cells with CQ (20 μM, 2 h)
prior to treatment with ponatinib (5 μM, 1 h) significantly
reduced the ponatinib Raman signal in both cell lines (Figure
5b−e)
Quantification of ponatinib signal inside lysosomes demon-
strated that CQ treatment reduced mean ponatinib concen-
tration in the lysosomes 2.7- and 3.8-fold in the KCL22 and
KCL22Pon‑Res cells, respectively, compared to ponatinib alone
(Figure 5c,d). To determine whether the inhibition of
autophagy by CQ also contributed to the reduced lysosomal
accumulation of ponatinib, we used KCL22Pon‑Res CRISPR-
ATG7 knockout cells. ATG7 is a critical autophagy regulator
and KCL22Pon‑Res CRISPR-ATG7 cells have a defect in the
autophagy pathway. KCL22Pon‑Res CRISPR-ATG7 and
KCL22Pon‑Res CRISPR-Control cells were simultaneously
treated with ponatinib (5 μM, 1 h) and labeled with
Lysotracker (50 nM, 1 h) before live imaging using SRS (SI,
Figure S3). Quantification of relative concentrations of
ponatinib by Raman intensity in individual cells of both cell
lines demonstrated no significant difference between the cell
lines, demonstrating that autophagy does not play a role in
ponatinib accumulation in lysosomes. Therefore, reduction of
ponatinib concentration in lysosomes upon CQ combination
treatment was likely due to the lysosomotropic properties of
CQ, which decreased the ability of ponatinib to accumulate in
the lysosomes.
Having found that CQ treatment significantly decreased
lysosomal trapping of ponatinib in both cell lines, we looked at
how this affected BCR-ABL inhibition. BCR-ABL is a cytosolic
tyrosine kinase and phosphorylation of CRKL (Tyr207), a
direct BCR-ABL substrate, was used as a surrogate for BCR-
ABL activity. Pretreatment with CQ significantly increased p-
CRKL inhibition at the lowest 10 nM ponatinib dose (Figure
5e,f, and SI, Figure S4). Thus, the reduced lysosome trapping
of ponatinib in the CQ treated cells increased BCR-ABL
inhibition. Interestingly, we saw a greater inhibition of pCRKL
phosphorylation in the KCL22Pon‑Res cells than in KCL22
ponatinib sensitive cells which correlates with the increased
cytoplasmic levels of ponatinib in the resistant cells (Figure 4f)
and supports a BCR-ABL independent mechanism of
ponatinib resistance.26 This is in contrast to the BCR-ABL
dependent resistance to other basic TKIs such as imatinib that
are used in the treatment of CML, where CQ can increase
target engagement with combined CQ and TKI treatments
resulting in enhanced efficacy.9,34
■ CONCLUSIONS
This study demonstrates the benefits of SRS microscopy in
providing real-time measurements of drug distribution in live
cells with high sensitivity and resolution. Use of SRS
microscopy has allowed label-free imaging of the TKI
ponatinib at biologically relevant concentrations and provided
Figure 5. Multimodal imaging and quantitative assessment of the effect of chloroquine treatment on the vesicular uptake of ponatinib. KCL22 and
KCL22Pon‑Res cells were treated with (a) ponatinib (5 μM, 1 h), (b) chloroquine (20 μM, 2 h) followed by combination treatment of ponatinib (5
μM, 1 h) and chloroquine (20 μM, 1 h). Images shown (left to right) 2221 cm−1 (CC, ponatinib), overlay TPF image at 861 nm (Lysotracker
Green) merged with 2221 cm−1. (c,d) Mean ponatinib Raman intensity inside the vesicles of each individual cell quantified in (c) KCL22 and (d)
KCL22Pon‑Res cell line, n = 10 cells, three biological repeats. Images acquired at 1024 × 1024 pixels, 20 μs pixel dwell time with false colors applied
to different detection wavenumbers. Scale bars: 10 μm. (e,f) p-CRKL level quantification from Western blots where KCL22 and KCL22Pon‑Res cells
were treated with (left to right) either DMSO (0.0003%, v/v), ponatinib (10, 100, 500 nM, 1 h), or a combination of chloroquine (20 μM, 2 h)
pretreatment and ponatinib (10, 100, or 500 nM, 1 h). p-CRKL level was quantified against α-tubulin control and normalized to DMSO using
Image Lab Software. One-Way ANOVA (Tukey’s multiple comparisons test) was used to compare ponatinib (10 nM) alone vs CQ combination
treatment.
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insight into changes in uptake and sequestration of drug that
has occurred during the development of acquired drug
resistance. We show that tuning the pump wavelength to the
alkyne stretch within ponatinib allows SRS imaging within the
Raman cellular-silent region following treatment with nano-
molar concentrations of ponatinib. Although imaging within
the cell silent region increases sensitivity, the recent
demonstration that Raman imaging of drugs may also be
achieved in the fingerprint region when the drug is enriched in
subcellular locales, opens up the possibility of label-free
imaging for a wider number of drug candidates and
metabolites.9,16 Furthermore, the addition of small alkyne
tags or deuterium substitutions to enable SRS imaging of drugs
and small molecules in the cellular-silent region with increased
sensitivity, further extends the potential for this technology to
provide read-outs of drug kinetics and mechanism of
action.10,17,35,36 Combined with DFT calculations and LC-
MS measurements, SRS imaging could be transformative to the
drug discovery pipeline by providing important information on
drug localization, mechanism of action, and target engagement.
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